These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33412557)

  • 1. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
    Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
    Altcheh J; Sierra V; Ramirez T; Pinto Rocha JJ; Grossmann U; Huang E; Moscatelli G; Ding O
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0119322. PubMed ID: 36975790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
    Rivero R; Esteva MI; Huang E; Colmegna L; Altcheh J; Grossmann U; Ruiz AM;
    PLoS Negl Trop Dis; 2023 Jun; 17(6):e0011440. PubMed ID: 37352322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.
    Falk N; Berenstein AJ; Moscatelli G; Moroni S; González N; Ballering G; Freilij H; Altcheh J
    Antimicrob Agents Chemother; 2022 May; 66(5):e0202121. PubMed ID: 35416710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR.
    Solari A; Ortíz S; Soto A; Arancibia C; Campillay R; Contreras M; Salinas P; Rojas A; Schenone H
    J Antimicrob Chemother; 2001 Oct; 48(4):515-9. PubMed ID: 11581230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina.
    Vizcaya D; Grossmann U; Kleinjung F; Zhang R; Suzart-Woischnik K; Seu S; Ramirez T; Colmegna L; Ledesma O
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009801. PubMed ID: 34606501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment.
    Jackson Y; Chatelain E; Mauris A; Holst M; Miao Q; Chappuis F; Ndao M
    BMC Infect Dis; 2013 Feb; 13():85. PubMed ID: 23406191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
    Abbott A; Montgomery SP; Chancey RJ
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):371-374. PubMed ID: 35271563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.
    Jurado Medina L; Chassaing E; Ballering G; Gonzalez N; Marqué L; Liehl P; Pottel H; de Boer J; Chatelain E; Zrein M; Altcheh J
    Lancet Infect Dis; 2021 Aug; 21(8):1141-1150. PubMed ID: 33836157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid].
    Rassi A; Amato Neto V; de Siqueira AF; Ferriolli Filho F; Amato VS; Rassi GG; Rassi Junior A
    Rev Soc Bras Med Trop; 2002; 35(6):547-50. PubMed ID: 12612733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of nifurtimox for the treatment of chronic Chagas disease].
    Fuentes B R; Maturana A M; de la Cruz M R
    Rev Chilena Infectol; 2012 Feb; 29(1):82-6. PubMed ID: 22552516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.
    Forsyth CJ; Hernandez S; Olmedo W; Abuhamidah A; Traina MI; Sanchez DR; Soverow J; Meymandi SK
    Clin Infect Dis; 2016 Oct; 63(8):1056-1062. PubMed ID: 27432838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.